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Abstract
Objective: To investigate and compare two ALS staging systems, King’s clinical staging and Milano-Torino (MiToS)
functional staging, using data from the LiCALS phase III clinical trial (EudraCT 2008-006891-31).Methods: Disease stage
was derived retrospectively for each system from the ALS Functional Rating Scale-Revised subscores using standard
methods. The two staging methods were then compared for timing of stages using box plots, correspondence using chi-
square tests, agreement using a linearly weighted kappa coefficient and concordance using Spearman’s rank correlation.
Results: For both systems, progressively higher stages occurred at progressively later proportions of the disease course, but
the distribution differed between the two methods. King’s stage 3 corresponded to MiToS stage 1 most frequently, with
earlier King’s stages 1 and 2 largely corresponding to MiToS stage 0 or 1. The Spearman correlation was 0.54. There was
fair agreement between the two systems with kappa coefficient of 0.21. Conclusion: The distribution of timings shows that
the two systems are complementary, with King’s staging showing greatest resolution in early to mid-disease corresponding
to clinical or disease burden, and MiToS staging having higher resolution for late disease, corresponding to functional
involvement. We therefore propose using both staging systems when describing ALS.
KEYWORDS: Clinical stage, MiToS stage, King’s stage, prognosis, clinical trials
Introduction
Amyotrophic lateral sclerosis (ALS), also known as
motor neuron disease (MND), is a progressive
neurodegenerative disease of motor neurons in the
brain and spinal cord, resulting in progressive
paralysis, with death typically within two to five
years of diagnosis (1). Although the cumulative
lifetime risk of ALS is 1 in 300 (2), the point
prevalence is only about 5 per 100,000 persons
because of the poor prognosis. The needs of
patients differ as ALS progresses, with diagnosis
and therapist support being important early on, and
respiratory intervention, nutritional intervention
and end-of-life care at a later stage.
Various ALS staging methods have been pro-
posed, with uses such as a tool for rehabilitation (3),
rapid functional assessment (4), comparison of
different treatment models (5,6), biomarker analysis
(7) and health economics (8). The El Escorial
criteria (9) provide a set of diagnostic guidelines that
are based on patterns of disease spread but are not
in themselves a staging system. The most widely
studied approaches have been the Milano-Torino
(MiToS) functional staging and King’s clinical
staging systems (10,11). The MiToS system uses
six stages, from 0 to 5 and is based on functional
ability as assessed by the ALS Functional Rating
Scale-Revised (ALSFRS-R) (12), with stage 0 being
normal function and stage 5 being death. The
King’s system uses five stages, from 1 to 5 and is
based on disease burden as measured by clinical
involvement and significant feeding or respiratory
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failure, with stage 1 being symptom onset and stage
5 being death. The King’s system is not based on
ALSFRS-R scores, but can be estimated from them
with 92% concordance (13).
Although the two systems both measure stage
and show content validity, mapping correctly to
disease progression, it is not clear to what extent
they are collinear and therefore redundant. We
therefore set out to compare the systems using
data from a phase III randomised double-blind
placebo-controlled trial of lithium carbonate in ALS
(LiCALS) (EudraCT number 2008-006891-31)
(14), in which ALSFRS-R scores were recorded at
three-monthly intervals.
Methods
Patients
Anonymised data from the LiCALS clinical trial
were reanalysed. Data consisted of ALSFRS-R
scores, site of disease onset (bulbar or limb),
gastrostomy timing, measures of respiratory func-
tion, and timing of non-invasive ventilation, rec-
orded every three months during an 18-month trial
enrolment. For all patients, date of death or last
follow-up were also recorded.
Clinical staging systems
ALS clinical stage comparisons were undertaken
using two staging systems: King’s clinical staging
and MiToS functional staging. As stages were not
previously recorded during the LiCALS clinical
trial, stages for both systems were determined
retrospectively and derived from historical data, as
previously described (10,11) (Figure 1). For sim-
plicity, we encoded King’s stages with prefix K, and
MiToS stages with prefix M, so, for example, K2M3
would represent King’s stage 2 and MiToS stage 3.
Statistical analysis
A Kaplan-Meier survival analysis and log-rank test
were used to test differences in survival from disease
onset for each categorical variable, site of onset
(bulbar or spinal), family history (sporadic ALS or
familial ALS), gender, and age of onset in 10-year
categories. We also tested the proportion of patients
dead or alive using a chi-square test after censoring
the date of death or last observation for all patients
to 30 June 2011.
Standardised median times for reaching clinical
stages were calculated as a proportion of time
elapsed from onset to each disease stage across the
duration of the disease for both King’s and MiToS
systems, with 0 representing symptom onset, and 1,
death, using only data from deceased patients, as
previously described (11).
Spearman’s coefficient was used to test overall
correlation between the two systems. Pairwise com-
parisons between the number of patients in each
King’s and MiToS stage were used to test the
relationship between specific stages using a chi-
square test. Standardised residuals were used to test
which items were most responsible for any associ-
ations observed. Agreement between the two ordinal
scales was tested using a linearly weighted kappa
coefficient.
Kappa coefficient was calculated using
VassarStats (http://vassarstats.net/kappa.html). All
other statistical tests were carried out using SPSS
v22.0 (SPSS Inc, Illinois, USA).
Ethics
The LiCALS clinical study was approved by the
South East London Research Ethics Committee,
reference 09/H1102/15. All participants involved
provided written consent. This current study does
not require ethics approval due to analysis being
conducted on fully anonymised pre-existing clinical
trial data.
Results
Patient characteristics
Data were available for 217 patients, of whom 95
had died by the censor date. Patient characteristics
are shown in Table 1. Median survival was 43.6
months, which is similar to that found in a previous
study using referral clinic data of 42.3 months (11).
There were no significant differences in survival by
Figure 1. Flowchart of ALS staging systems and their definitions (King’s staging and MiToS staging).
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gender, family history or site of onset, and no
differences were seen in the proportion still alive by
the study end-date. Older age at disease onset was
associated with worse survival, p¼ 0.01, and con-
sistent with this observation, the proportion of
deaths compared with censored observations pro-
gressively increased as patients were classified into
higher age groups: 56% of patients in the 75–84-
years age group had died by the end of the trial,
compared with only 14% for the 25–34-years
age group.
Standardised median time
Ninety-five patients had died by the end of the
study. The standardised median proportion of time
elapsed from onset to each King’s stage is shown in
Table 2a and Figure 2(a). Corresponding values
for MiToS stages are shown in Table 2b and
Figure 2(b), showing a wider distribution of King’s
stages through the early and middle disease course,
compared with a tendency for MiToS stages to be
distributed later in the disease course.
Comparison of staging systems
To compare each staging system, King’s and MiToS
scores were plotted against frequency for all pairwise
comparisons (Figure 3). King’s stages 1 and 2
matched mostly with MiToS stages 0 or 1 (K1M0
n¼ 151, K2M0 n¼ 210, K1M1 n¼ 35, K2M1
n¼ 100) with little overlap to MiToS stage 2
(K2M2 n¼ 4) and none with MiToS stages 3 and
4. However, for King’s stage 3, although the
majority was paired with MiToS stages 0 or 1
(K3M0 n¼ 203, K3M1 n¼ 211), more patients
were defined as MiToS stages 2 (K3M2 n¼ 37) and
3 (K3M3 n¼ 11). In King’s stage 4 all four MiToS
stages were seen (K4M0 n¼ 8, K4M1 n¼ 60,
K4M2 n¼ 77, K4M3 n¼ 24, K4M4 n¼ 6).
A chi-square test confirmed association between
some stages with the two staging systems (p50.001)
and standardised residuals showing the strongest
association were of King’s stage 4 with MiToS
stage 2. A Spearman’s rank correlation coefficient
between the King’s and MiToS systems showed a
correlation of 0.54. A linearly weighted kappa
agreement between the two systems highlighted a
Table 1. Characteristics of LiCALS patients. Median time to death or last observation and percentage of death at last observation
compared using different categories (gender, site of onset, family history and age of onset).
n (%)
Median time to death
or last observation
in months (95% CI) p-value
Death at last
observation (%) p-value
Gender p¼ 0.19 p¼0.13
Male 151 (70) 47.8 (39.0-56.6) 61 (40)
Female 66 (30) 37.9 (32.0-43.9) 34 (52)
Site of Onset p¼ 0.24 p¼0.60
Limb 170 (78) 40.1 (32.8-47.3) 76 (45)
Bulbar 47 (22) 47.8 (–) 19 (40)
Type p¼ 0.91 p¼0.60
Sporadic 211 (97) 43.6 (36.6-50.5) 93 (44)
Familial 6 (3) – (–) 2 (33)
Age p¼ 0.01 p¼0.02
25-34 7 (3) – (–) 1 (14)
35-44 16 (7) – (–) 4 (25)
45-54 58 (27) – (–) 18 (31)
55-64 75 (35) 34.4 (29.0-39.7) 41 (55)
65-74 52 (24) 37.9 (32.3-42.9) 26 (50)
75-84 9 (4) 32.2 (20.0-44.3) 5 (56)
Total 217 (100) 43.6 (36.6-50.5) 95 (44)
Censor date was 30/06/2011
Table 2. Median number of months and Standardised Median
Time (SMT) from onset to each stage. (A) King’s staging system,
(B) MiToS staging system. Patients dead on last observation were
recorded and median time from onset to each stage used
and repeated for each stage in both staging systems.
IQR¼ Interquartile range.
A)
King’s staging
system (n)
Median number of
months from onset
(IQR) SMT (IQR)
1 (95) 9.0 (5.4–13.0) 0.33 (0.24–0.46)
2 (49) 18.4 (12.8–22.6) 0.62 (0.51–0.73)
3 (67) 18.9 (12.6–24.6) 0.67 (0.55–0.82)
4 (32) 24.8 (17.4–30.9) 0.86 (0.79–0.95)
5 (95) 27.7 (22.0–34.0) 1.00 (1.00–1.00)
B)
Milano-Torino
staging system
(n)
Median number of
months from onset
(IQR) SMT (IQR)
0 (95) 9.0 (5.4–12.9) 0.33 (0.24–0.46)
1 (94) 16.5 (11.9–22.1) 0.58 (0.49–0.71)
2 (37) 25.0 (20.0–31.7) 0.88 (0.72–0.93)
3 (12) 25.1 (21.0–30.0) 0.93 (0.86–0.97)
4 (2) 27.0 (24.1–29.8) 0.95 (0.95–0.96)
5 (95) 27.7 (22.0–34.0) 1.00 (1.00–1.00)
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kappa coefficient of 0.21 with a 95% confidence
interval of 0.18–0.24.
Discussion
We have found that while the King’s clinical staging
system is able to differentiate early to mid-disease
well, the MiToS staging is able to differentiate late
stages in detail, which is in line with previous
findings (15). These results support the use of both
systems when staging, as they summarise two
different aspects of patient information. King’s
staging is mostly focused on anatomical disease
spread and significant involvement of respiratory
muscles, whereas MiToS staging is aimed more
towards the distinction of functional capabilities
during the spread of the disease. Because functional
engagement necessarily follows anatomical
Figure 2. Box plot for Standardised Median Time (SMT) from onset to each disease stage. (A) SMT for King’s stages. (B) SMT for
MiToS stages. The y-axis represents the proportion of disease time elapsed, where 0 is disease onset and 1 is death. Horizontal lines on
each plot represent the following: minimum, lower quartile, median, upper quartile and maximum values, read from bottom to top. Mean
values are marked by ‘x’ and outliers by ‘’.
Figure 3. Three-dimensional bar chart showing the count of patients in each clinical stage by both systems. The y-axis represents the
number of patients, x-axis the MiToS stage (0-4) and z-axis the King’s stage (1–4) of disease progression.
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involvement, MiToS stages inevitably tend to lag
behind King’s stages, manifesting as a higher reso-
lution later on in the disease. This is most clearly
seen in Figure 3, where the relative distribution of
individuals in each staging system is shown. The
MiToS stages remain at a low resolution for the
majority of King’s stages up to K4, at which point
there is significant differentiation of the MiToS
stages. These findings should be validated in a
prospective study.
These differences in disease description by the
two systems are also shown by a Spearman’s rank
correlation of 0.54, showing some correspondence
between the two systems. Association testing shows
that King’s stage 4 and MiToS stage 2 are the most
strongly associated between all staging pairs.
Linearly weighted kappa coefficient tests the
strength of agreement between two ordinal scales
with increase of penalty based on the level of
disagreement. A commonly used scale to interpret
kappa values, ranges from 0 (chance agreement) to 1
(perfect agreement) with intervals of poor, slight,
fair, moderate, substantial and almost perfect (16).
Our analysis between King’s and MiToS staging
systems showed a fair agreement with a linearly
weighted kappa coefficient of 0.21.
Examination of the proportion of disease elapsed
at each stage confirms that King’s stages show more
resolution through early to mid-disease and MiToS
stages towards the end. Patients in King’s stages 1, 2
and 3 are often in MiToS stages 0 or 1. We found
that King’s Stage 4 corresponds to MiToS stages 2,
3 and 4, and about 80–90% of the disease course.
The benefit of MiToS staging in differentiating later
stages of disease is in contrast to the ALSFRS-R
scores from which it was derived, that exhibits a
floor effect and lack of sensitivity in the later stages
(10–12) i.e. by combining information from differ-
ent parts of the ALSFRS-R, MiToS staging is able
to provide value over and above the ALSFRS-R
score as a functional indicator for disease
progression.
A limitation of this study is its use of clinical trial
data rather than clinic or population data. However,
this may be advantageous, as results are more likely
to be relevant to daily clinical practice. We have
previously shown that clinical trial data show a shift
towards a greater proportion of disease-course
passed for a given stage (13). This occurrence is
probably a result of left censoring due to the
population being selected for trial participation
and sourced from a biased clinic population.
The two disease staging systems described are
complementary rather than redundant, and provide
different types of information. King’s staging sum-
marises the clinical or anatomical spread of disease,
while MiToS staging summarises the functional
burden of disease. A similar situation exists for
cancers. The American Joint Committee on
Cancer’s TNM scale allocates a score for size,
lymph node infiltration and metastasis as a func-
tional indicator for disease progression (17), and
this is combined with grouping of patients into
one of four clinical stages that determine overall
disease progression. King’s stage prefixed K, and
MiToS stage prefixed M, would allow a concise
summary of disease spread and functional burden.
We therefore propose using both to describe ALS
stage.
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